A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer

2014 ◽  
Vol 50 (18) ◽  
pp. 3136-3144 ◽  
Author(s):  
Tamas Hickish ◽  
Jim Cassidy ◽  
David Propper ◽  
Ian Chau ◽  
Stephen Falk ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Open Label ◽  
Open Label Phase

Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: a nonrandomized, open-label, phase II trial

2014 ◽  
Vol 73 (4) ◽  
pp. 695-702 ◽  
Author(s):  
Carlos R. Becerra ◽  
Ramon Salazar ◽  
Rocio Garcia-Carbonero ◽  
Anne L. Thomas ◽  
Federico J. Vázquez-Mazón ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Open Label ◽  
Open Label Phase ◽  
Previously Treated

scholarly journals An Open‐Label Phase II Study Evaluating the Safety and Efficacy of Ramucirumab Combined With mFOLFOX‐6 as First‐Line Therapy for Metastatic Colorectal Cancer

2014 ◽  
Vol 19 (4) ◽  
pp. 350-351 ◽  
Author(s):  
Rocio Garcia‐Carbonero ◽  
Fernando Rivera ◽  
Joan Maurel ◽  
Jean‐Pierre M. Ayoub ◽  
Malcolm J. Moore ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
First Line ◽  
Open Label ◽  
Safety And Efficacy ◽  
First Line Therapy ◽  
Line Therapy ◽  
Open Label Phase

An open-label phase II study of intermittent oral capecitabine (X) as first-line treatment for patients (pts) with metastatic colorectal cancer (MCRC)

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 3730-3730
Author(s):  
G. Zhongzhen ◽  
F. Fengyi ◽  
L. Xiaoqing ◽  
W. Yajie ◽  
Y. Baoming ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Line Treatment ◽  
First Line ◽  
Open Label ◽  
Oral Capecitabine ◽  
Open Label Phase ◽  
First Line Treatment

scholarly journals Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE): A Single-arm, Open-label, Phase II Trial

2021 ◽  
Author(s):  
Sophie Cousin ◽  
Coralie Cantarel ◽  
Jean-Philippe Guegan ◽  
Carlos Gomez-Roca ◽  
Jean-Philippe Metges ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Open Label ◽  
Open Label Phase

scholarly journals Oral S-1 with 24-h Infusion of Irinotecan plus Bevacizumab versus FOLFIRI plus Bevacizumab as First-Line Chemotherapy for Metastatic Colorectal Cancer: An Open-Label Randomized Phase II Trial

Oncology ◽  
2020 ◽  
Vol 98 (9) ◽  
pp. 637-642
Author(s):  
Sotaro Sadahiro ◽  
Toshiyuki Suzuki ◽  
Kazutake Okada ◽  
Gota Saito ◽  
Hiroshi Miyakita ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
First Line ◽  
Open Label ◽  
Randomized Phase Ii ◽  
Line Chemotherapy

scholarly journals 523TiP MOUNTAINEER: Open-label, phase II study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer

2020 ◽  
Vol 31 ◽  
pp. S460-S461
Author(s):  
J. Strickler ◽  
K. Ng ◽  
A. Cercek ◽  
C. Fountzilas ◽  
F. Sanchez ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Her2 Positive ◽  
Open Label ◽  
Open Label Phase

Bendamustine, Followed by Ofatumumab and Ibrutinib in Chronic Lymphocytic Leukaemia (CLL2-BIO): Primary Endpoint Analysis of a Multicentre, Open-Label Phase-II Trial

2019 ◽  
Author(s):  
Paula Cramer ◽  
Julia V. Tresckow ◽  
Sandra Robrecht ◽  
Jasmin Bahlo ◽  
Moritz Fürstenau ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukaemia ◽  
Phase Ii ◽  
Primary Endpoint ◽  
Lymphocytic Leukaemia ◽  
Phase Ii Trial ◽  
Open Label ◽  
Open Label Phase
Sign in / Sign up

Export Citation Format

Share Document